Xbrane Biopharma Q1 2025: Transformative times - Redeye

Redeye updates its view on Xbrane following a stronger-than-expected Q1 report, with both revenue and EBIT exceeding estimates. In the wake of the Alvotech deal, we see a new investment case emerging—still overshadowed by the turbulence of the past year, the current market cap remains modest for a commercial-stage biotech company.

Länk till analysen i sin helhet: https://www.redeye.se/research/1100078/xbrane-biopharma-q1-2025-transformative-times?utm_source=finwire&utm_medium=RSS